{'fraction_non_alphanumeric': 0.03094059405940594, 'fraction_numerical': 0.01608910891089109, 'mean_word_length': 5.631147540983607, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Efficacy of etretinate for the PUVA‐dependent Psoriatic

Twenty‐three adult patients (13 males, 10 females) with psoriasis vulgaris had been on long‐term PUVA maintenance therapy (mean 4 years 2 months, 210 PUVA exposures). Their psoriasis had broken through PUVA maintenance or relapsed rapidly on discontinuing PUVA. The aromatic retinoid etretinate (Tigason®) was commenced to reduce the dose of PUVA required to control their psoriasis. Four patients subsequently cleared on etretinate alone, 11 cleared on the etretinate‐PUVA combination. Five patients improved short of complete clearing and one remained unchanged although his PUVA doses were reduced. The remaining: two patients responded poorly due to non‐compliance and side‐effects respectively. Overall a 58% reduction in UVA doses was estimated.